Viaskin Peanut stands out as DBV Technologies’ primary asset, with analysts projecting blockbuster potential due to its unique approach to peanut allergy treatment. The epicutaneous therapy ...

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of ...

Explore DBV Technologies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DBVT. DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In ...

DBV Technologies stock opened at $4.19 on Thursday. The firm has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $3.83. The stock has a market capitalization of $86. ...

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

The NFL Combine continues on Friday, with the spotlight shifting to defensive backs and tight ends as they take the field for workouts.

Along with Comey, the statement was signed by Robert B. Fiske Jr., John S. Martin Jr., Mary Jo White, David N. Kelley, Geoffrey S. Berman and Audrey Strauss. He was to stand trial in April ...